AA
AlphaCentric Advisors’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $503K | Sell |
3,684
-18,816
| -84% | -$2.57M | 0.5% | 56 |
|
|
2024
Q3 | $2.59M | Buy |
22,500
+15,500
| +221% | +$1.79M | 1.93% | 6 |
|
|
2024
Q2 | $964K | Hold |
7,000
| – | – | 0.71% | 49 |
|
|
2024
Q1 | $965K | Buy |
+7,000
| New | +$965K | 0.58% | 64 |
|
|
2023
Q4 | – | Sell |
-30,000
| Closed | -$3.38M | – | 269 |
|
|
2023
Q3 | $3.38M | Sell |
30,000
-6,500
| -18% | -$731K | 1.91% | 9 |
|
|
2023
Q2 | $3.44M | Buy |
36,500
+21,000
| +135% | +$1.98M | 1.91% | 7 |
|
|
2023
Q1 | $1.57M | Buy |
+15,500
| New | +$1.57M | 1.08% | 22 |
|
|
2021
Q2 | – | Sell |
-2,000
| Closed | -$195K | – | 233 |
|
|
2021
Q1 | $195K | Sell |
2,000
-800
| -29% | -$78K | 0.07% | 94 |
|
|
2020
Q4 | $268K | Buy |
2,800
+2,500
| +833% | +$239K | 0.11% | 47 |
|
|
2020
Q3 | $29K | Buy |
300
+75
| +33% | +$7.25K | 0.01% | 131 |
|
|
2020
Q2 | $27K | Buy |
+225
| New | +$27K | 0.02% | 107 |
|